Table 2.
Mean (SD) area under the time–response curve (AUC) for FEV1 and the systemic measurements, made at intervals over 4 h for each rac-formoterol dose
| FEV1 (mm h−1) | SpO2 (ml h−1) | Dyspnoea (% h−1) | HR (mm h−1) | Tremor (bpm h−1) | VAS tremor (m s−1 s−1 h−1) | SBP (mmHg h−1) | DBP | |
|---|---|---|---|---|---|---|---|---|
| Placebo | −104.3 (59) | 0.5 (0.2) | −25 (12) | −8.9 (2.3) | −0.42 (0.1) | −3.2 (2.1) | −21 (5) | −6.7 (3) |
| 6 μg | 225.3† (50) | 1.2 (0.5) | −46.0 (15) | −2.8 (0.8) | −0.26 (0.1) | −4.6 (3.0) | −3.3 (2) | 1.5 (1) |
| 12 μg | 362† (101) | 0.3 (0.2) | −38.2 (19) | −2.5 (0.8) | −0.12 (0.05) | −20.7 (7.0) | −4.1 (2) | 3.1 (2) |
| 24 μg | 510.8† (299) | −1.0 (0.2) | −46.2 (28) | −6.3 (2.3) | 0.57† (0.2) | 0.6 (10) | 8.2 (3) | 3.6 (2) |
| 48 μg | 626.6† (297) | 1.1 (0.4) | −44.3 (19) | 0.6† (3.3) | 0.85† (0.4) | 1.5 (5) | 3.9 (3) | 8.4 (5) |
| P-value | 0.04* | 0.69 | 0.98 | 0.65 | <0.001* | 0.04* | 0.6 | 0.68 |
*
P = 0.05 for dose–response trend.
†
P = 0.05 for individual rac-formoterol dose vs. placebo. FEV1, forced expiratory volume in 1 s; HR, heart rate; VAS, visual analogue scale.